Jarden Research Adjusts Telix Pharmaceuticals' Price Target to AU$27.61 from AU$29.14; Keeps at Buy

Like
1
Favorite

Jarden Research Adjusts Telix Pharmaceuticals' Price Target to AU$27.61 from AU$29.14; Keeps at Buy

MT Newswires Live08-06

Telix Pharmaceuticals (ASX:TLX) has an average rating of overweight and mean price target of AU$31.44, according to analysts polled by FactSet.

(MT Newswires covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www.mtnewswires.com/contact-us)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Report

Comment（1）

Anton 89
·08-07
Telix (TLX.AX) – What Just Happened? A Quick Summary for Investors A couple of seemingly conflicting reports have dropped this week regarding Telix Pharmaceuticals, so here’s a plain-English breakdown of what’s going on, what it might mean, and where things could go from here. 🧾 The News Morningstar Cuts EBIT Forecasts (6 Aug – Reuters) Morningstar reduced its EBIT (earnings before interest and taxes) forecasts for Telix by an average of 29% over the next two years. Reason: Delays in cost efficiencies from Telix’s recent US acquisition of RLS Radiopharmacies. Operating Expenses (OPEX) for H1 FY25 are now forecast at 36% of revenue, up from 28% last year (though some investor analysis suggests last year’s figure was closer to 93%, raising questions). Despite the lowered EBIT forecasts, Morn
Reply
1
Report

Most Discussed

7x24

All

{"i18n":{"language":"en_US"},"data":{"share":"https://ttm.financial/m/news/2557327307?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-08-06 17:45","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2557327307","market":"hk","top_or_hot":-1,"title":"Jarden Research Adjusts Telix Pharmaceuticals' Price Target to AU$27.61 from AU$29.14; Keeps at Buy","media":"MT Newswires Live","content":"<html><body><p> <a href=\"https://laohu8.com/S/TLX.AU\">Telix Pharmaceuticals</a> (ASX:TLX) has an average rating of overweight and mean price target of AU$31.44, according to analysts polled by FactSet.</p><p>(MT Newswires covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www.mtnewswires.com/contact-us)</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Jarden Research Adjusts Telix Pharmaceuticals' Price Target to AU$27.61 from AU$29.14; Keeps at Buy</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nJarden Research Adjusts Telix Pharmaceuticals' Price Target to AU$27.61 from AU$29.14; Keeps at Buy\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2025-08-06 17:45</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> <a href=\"https://laohu8.com/S/TLX.AU\">Telix Pharmaceuticals</a> (ASX:TLX) has an average rating of overweight and mean price target of AU$31.44, according to analysts polled by FactSet.</p><p>(MT Newswires covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www.mtnewswires.com/contact-us)</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"TLX","symbol_name":"Telix Pharmaceuticals Ltd. (Uplisting)","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2557327307","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2557327307","pubTimestamp":1754473529,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Telix Pharmaceuticals (ASX:TLX) has an average rating of overweight and mean price target of AU$31.44, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic resea","collect":0,"end_time":0,"defaultTopTitle":"","property":["rate","earning"],"viewcount":null,"language":"en","relate_stocks":{"TLX":"Telix Pharmaceuticals Ltd. (Uplisting)","TLX.AU":"TELIX PHARMACEUTICALS LTD"},"translate_title":"Jarden Research将Telix Pharmaceuticals目标价从29.14澳元调整至27.61澳元；继续买入","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"TLX.AU":0.9,"TLX":1},"content_text":"Telix Pharmaceuticals (ASX:TLX) has an average rating of overweight and mean price target of AU$31.44, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www.mtnewswires.com/contact-us)","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"express","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[{"id":464807697981776,"gmtCreate":1754526610564,"gmtModify":1754531257952,"author":{"id":"4183091609998932","authorId":"4183091609998932","name":"Anton 89","avatar":"https://community-static.tradeup.com/news/default-avatar.jpg","vip":1,"crmLevel":12,"crmLevelSwitch":0,"idStr":"4183091609998932","authorIdStr":"4183091609998932"},"htmlText":"Telix (TLX.AX) – What Just Happened? A Quick Summary for Investors A couple of seemingly conflicting reports have dropped this week regarding Telix Pharmaceuticals, so here’s a plain-English breakdown of what’s going on, what it might mean, and where things could go from here. 🧾 The News Morningstar Cuts EBIT Forecasts (6 Aug – Reuters) Morningstar reduced its EBIT (earnings before interest and taxes) forecasts for Telix by an average of 29% over the next two years. Reason: Delays in cost efficiencies from Telix’s recent US acquisition of RLS Radiopharmacies. Operating Expenses (OPEX) for H1 FY25 are now forecast at 36% of revenue, up from 28% last year (though some investor analysis suggests last year’s figure was closer to 93%, raising questions). Despite the lowered EBIT forecasts, Morn","listText":"Telix (TLX.AX) – What Just Happened? A Quick Summary for Investors A couple of seemingly conflicting reports have dropped this week regarding Telix Pharmaceuticals, so here’s a plain-English breakdown of what’s going on, what it might mean, and where things could go from here. 🧾 The News Morningstar Cuts EBIT Forecasts (6 Aug – Reuters) Morningstar reduced its EBIT (earnings before interest and taxes) forecasts for Telix by an average of 29% over the next two years. Reason: Delays in cost efficiencies from Telix’s recent US acquisition of RLS Radiopharmacies. Operating Expenses (OPEX) for H1 FY25 are now forecast at 36% of revenue, up from 28% last year (though some investor analysis suggests last year’s figure was closer to 93%, raising questions). Despite the lowered EBIT forecasts, Morn","text":"Telix (TLX.AX) – What Just Happened? A Quick Summary for Investors A couple of seemingly conflicting reports have dropped this week regarding Telix Pharmaceuticals, so here’s a plain-English breakdown of what’s going on, what it might mean, and where things could go from here. 🧾 The News Morningstar Cuts EBIT Forecasts (6 Aug – Reuters) Morningstar reduced its EBIT (earnings before interest and taxes) forecasts for Telix by an average of 29% over the next two years. Reason: Delays in cost efficiencies from Telix’s recent US acquisition of RLS Radiopharmacies. Operating Expenses (OPEX) for H1 FY25 are now forecast at 36% of revenue, up from 28% last year (though some investor analysis suggests last year’s figure was closer to 93%, raising questions). Despite the lowered EBIT forecasts, Morn","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/464807697981776","repostId":2557327307,"repostType":2,"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"}],"hasMoreComments":true,"newsSizeData":{"likeSize":0,"commentSize":1,"repostSize":1,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"isCrawlerRequest":true}